Skip to content
2000
image of Drug Safety Signals for Pediatric Osteopenia and Osteoporosis: 
Disproportionality Analysis of USFDA Adverse Event Reporting System Analysis

There is no abstract available.

Loading

Article metrics loading...

/content/journals/cpr/10.2174/0115733963375307250521100744
2025-05-23
2025-10-31
Loading full text...

Full text loading...

/deliver/fulltext/cpr/10.2174/0115733963375307250521100744/BMS-CPR-2024-115.html?itemId=/content/journals/cpr/10.2174/0115733963375307250521100744&mimeType=html&fmt=ahah

References

  1. Galindo-Zavala R. Bou-Torrent R. Magallares-López B. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr. Rheumatol. Online J. 2020 18 1 20 [http://dx.doi.org/10.1186/s12969-020-0411-9]. [PMID: 32093703].
    [Google Scholar]
  2. Uziel Y. Zifman E. Hashkes P.J. Osteoporosis in children: Pediatric and pediatric rheumatology perspective: A review. Pediatr. Rheumatol. Online J. 2009 7 1 16 [http://dx.doi.org/10.1186/1546-0096-7-16]. [PMID: 19835571].
    [Google Scholar]
  3. Ciancia S. van Rijn R.R. Högler W. Osteoporosis in children and adolescents: When to suspect and how to diagnose it. Eur. J. Pediatr. 2022 181 7 2549 2561 [http://dx.doi.org/10.1007/s00431-022-04455-2]. [PMID: 35384509].
    [Google Scholar]
  4. Bowles S.K. Drug-induced osteoporosis. Women’s and Men’s Health. Available from 2024
    [Google Scholar]
  5. Mazziotti G. Canalis E. Giustina A. Drug-induced osteoporosis: Mechanisms and clinical implications. Am. J. Med. 2010 123 10 877 884 [http://dx.doi.org/10.1016/j.amjmed.2010.02.028]. [PMID: 20920685].
    [Google Scholar]
  6. Lee W.J. Schumock G.T. Lee T.A. Drugs associated with adverse drug events in children: Analysis of the united states fda adverse event reporting system database. Value Health 2013 16 3 A70 [http://dx.doi.org/10.1016/j.jval.2013.03.311].
    [Google Scholar]
  7. Sridharan K. Sivaramakrishnan G. Adverse event profile of first-line drugs for treating patent ductus arteriosus in neonates: A disproportionality analysis study of USFDA adverse event reporting system. Paediatr. Drugs 2024 26 6 767 785 [http://dx.doi.org/10.1007/s40272-024-00657-3]. [PMID: 39367998].
    [Google Scholar]
  8. Wang Y.H. Wintzell V. Ludvigsson J.F. Svanström H. Pasternak B. Association between proton pump inhibitor use and risk of fracture in children. JAMA Pediatr. 2020 174 6 543 551 [http://dx.doi.org/10.1001/jamapediatrics.2020.0007]. [PMID: 32176276].
    [Google Scholar]
  9. Tabaie S.A. O’Mara A.E. Sheppard E.D. Tosi L.L. A comprehensive review of bone health in a child: From birth to adulthood. J. Am. Acad. Orthop. Surg. 2024 32 9 363 372 [http://dx.doi.org/10.5435/JAAOS-D-23-00853]. [PMID: 38261781].
    [Google Scholar]
  10. Ward L.M. A practical guide to the diagnosis and management of osteoporosis in childhood and adolescence. Front. Endocrinol. (Lausanne) 2024 14 1266986 [http://dx.doi.org/10.3389/fendo.2023.1266986]. [PMID: 38374961].
    [Google Scholar]
/content/journals/cpr/10.2174/0115733963375307250521100744
Loading
/content/journals/cpr/10.2174/0115733963375307250521100744
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.


  • Article Type:
    Editorial
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test